Owens & Minor, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMI research report →
Range $4 – $37
Price Chart
About the company
Owens & Minor, Inc. , along with its affiliated entities, operates as a global provider of healthcare solutions, serving markets both within the United States and internationally. Its business is structured into two primary divisions: Global Solutions and Global Products.
- CEO
- Edward A. Pesicka
- IPO
- 1980
- Employees
- 23,200
- HQ
- Mechanicsville, VA, US
Get TickerSpark's AI analysis on OMI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $2.76B-74.2%
- Gross Profit
- $0-100.0%
- Op Income
- $27.46M
- Net Income
- $-1,100,642,000-203.5%
- EPS
- $-14.24-201.1%
- OCF Growth
- -100.0%
- FCF Growth
- +100.0%
- 52W High
- $15.54
- 52W Low
- $1.91
- 50D MA
- $3.10
- 200D MA
- $5.77
- Beta
- 1.36
- RSI (14)
- 44
- Avg Volume
- 2.22M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Accendra reported a weak Q3 with revenue down modestly, margins pressured by payer-related and operational issues, and management signaling an active turnaround plan rather than an immediate recovery.· November 5, 2026
- Q3 revenue was just under $602 million, down 1% year over year excluding the large commercial payer loss and the sale of a non-core asset.
- Adjusted EBITDA was $47.8 million, while adjusted EBITDA plus non-cash convert-to-sale write-off expense less patient service equipment CapEx was just under $17 million.
- Sleep grew over 4% excluding the payer loss and asset sale, but diabetes fell nearly 3%, respiratory fell about 6.5%, and wound fell about 6%.
- Management said contractual allowance impact improved to $6 million favorable year over year, but collections are still disappointing.
- Full-year 2026 net revenue is now expected at the bottom of the prior $2.45 billion-$2.55 billion range, and adjusted EBITDA could be as much as 30% lower than the prior $310 million midpoint guidance.
Third-quarter revenue was just under $602 million, down 1% year over year excluding the impact of the large commercial payer loss and a non-core asset sale. Adjusted EBITDA was $47.8 million. Cost of net revenue was 56.6% of net revenue, 280 basis points higher than last year’s third quarter, and SG&A was 41.5% of net revenue versus 38.1% a year ago. Contractual allowance impact was $6 million favorable year over year, about $4 million better than the prior two quarters. Net debt was $1.73 billion, down $40 million versus December 31 and up $18 million from the end of June. Cash was $27 million and revolver borrowings were $35 million at September 30, with nearly $300 million of available liquidity sources. For 2026, management now expects full-year net revenue at the bottom of the prior $2.45 billion-$2.55 billion range, and adjusted EBITDA could be as much as 30% lower than the prior $310 million midpoint; Q4 adjusted EBITDA is expected to be comparable to Q3. Management also said about $14 million in proceeds is expected from the pending sale of a small non-core asset.
Kenny Gardner-Smith framed the quarter as disappointing but said the core issues are fixable and largely within management’s control. He emphasized that the problem is not the end markets or brands, but operating friction, slower and more costly intake, weak digital referral adoption, inconsistent sales execution, and poor patient retention in sleep and respiratory. His tone was determined and optimistic, with a focus on speed to value, a multi-year value creation plan, and visible changes already underway, including commercial reorganization and a revamped branch/back-office operating model.
Jonathan Leon said the quarter was extremely disappointing because near-term profit improvement efforts did not produce the expected results, but he stressed liquidity remains strong. He cited $47.8 million of adjusted EBITDA, 56.6% cost of net revenue, 41.5% SG&A, $27 million of cash, $35 million drawn on the revolver, and nearly $300 million of available liquidity. He also highlighted $94 million of one-time cash expenses in operating cash flow and $21 million in financing cash expenses for the first nine months, plus $35 million of year-to-date patient service equipment CapEx tied to the former large commercial payer contract; he said future CapEx should be meaningfully lower in 2027 and that the AR securitization was extended to October 2029 at $150 million.
The main analyst question focused on the commercial payer audits and whether any cash issues would spill into 2027, as well as how management plans to bridge the liquidity gap while turnaround actions take time. Leon said the audit issue is largely behind them, that they reached an agreement with at least one major payer, and that the remaining dollars are only “measured by millions on fingers on one hand,” with nothing expected to leak into 2027. On liquidity, Leon and Gardner-Smith said they do not expect to need significant additional borrowing, pointing to the strong balance sheet, continued working-capital benefit, and existing facilities as runway for the turnaround.
Management said the company has strong brands, attractive end markets, and issues that are mostly operational rather than structural. They believe the turnaround is already underway, with changes in commercial leadership, patient engagement, revenue-cycle management, and branch/back-office processes expected to improve growth, collections, and cost structure. They also pointed to strong liquidity and lower expected CapEx in 2027 as supporting the investment in the turnaround.
The call highlighted broad execution problems: lost share in sleep and respiratory, weaker referral flow, slower patient retention, and inadequate digital adoption. Revenue trends softened, SG&A rose, and adjusted EBITDA guidance was cut materially, with Q4 expected to be similar to Q3. Management also said 2027 timing and dollar impact are not yet ready to quantify, so the turnaround story remains early and uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.3%
- Shares Outstanding
- 77.26M
- Float Shares
- 74.37M
of shares held by institutions
216 13F filers
Buy/sell ratio 1.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for OMI, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 6.32M | ▲ 355.44K |
| Two Sigma Advisers, LP | 542.47K | ▲ 89.50K |
| Cubist Systematic Strategies, LLC | 123.63K | ▼ 43.77K |
| Nebula Research & Development LLC | 122.54K | ▼ 13.28K |
| Point72 Asia (Singapore) Pte. Ltd. | 69.45K | ▲ 48.27K |
| Corton Capital Inc. | 33.69K | ▲ 8.11K |
| Point72 (Difc) Ltd | 19.85K | ▼ 457.23K |
| Alphaquest LLC | 14.30K | 0 |
| Shell Asset Management Co | 8.81K | ▼ 9.77K |
| Comerica Bank | 3.28K | ▲ 332 |
| Stephens Consulting, LLC | 2.88K | 0 |
| Lindbrook Capital, LLC | 618 | ▼ 335 |
Held by 69 ETFs
Biggest fund positions in OMI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 17, 22 | Sarkar Snehashish | other | 0 |
| Nov 10, 20 | Lowry Michael Wayne | sell | 10,000 |
| May 11, 20 | Henkel Robert J | other | 17,242 |
| May 11, 20 | Henkel Robert J | buy | 10,000 |
| Aug 7, 19 | Beck Mark A | other | 0 |
| Dec 10, 18 | Pekala Joseph S | other | 0 |
| Jun 25, 18 | Connolly Timothy P | other | 0 |
| Aug 22, 16 | Olive Stephen Russell | other | 0 |
| Sep 21, 15 | Romans Michael Jay | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OMI coverage
Recent articles, reports, and earnings notes.
No research on OMI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OMI report →Orosur Mining falls 15% after discounted placing announcement
proactiveinvestors.com · Sep 23
Orosur Mining Inc Announces Holding(s) in Company
accessnewswire.com · Jul 13
Orosur Mining says new drilling has given fresh view of APTA gold prospect
proactiveinvestors.co.uk · Jun 9
Honda and the Honda USA Foundation Support Hundreds of Programs Expanding Opportunity Across the U.S.
gurufocus.com · Jun 3
Orosur Mining Inc Announces Total Voting Rights
accessnewswire.com · Jun 1
Orosur Mining Inc Announces Exercise of RSUs
accessnewswire.com · May 19
Orosur Mining Inc Announces Granting of RSUs
accessnewswire.com · May 1
Orosur Mining Inc. Announces Total Voting Rights
accessnewswire.com · Apr 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.